Patient characteristics at study entry (all eligible patients, n = 169)
| Characteristic . | Value . |
|---|---|
| Sex, female/male (%) | 28/141 (17/83) |
| Age, y | 51 (27-60) |
| IGHV unfavorable (%) | 87/91 (68) |
| Unmutated* (%) | 84/129 (65) |
| V3-21 mutated (%) | 4/129 (3) |
| FISH karyotype (hierarchical model) | |
| 17p- ± others (%) | 4/160 (2.5) |
| 11q- ± others (except 17p-) (%) | 40/160 (25) |
| +12 ± others (except 17p-, 11q-) (%) | 20/160 (12.5) |
| 13q- only (%) | 48/160 (30) |
| Others (%) | 20/160 (12.5) |
| Normal FISH karyotype (%) | 28/160 (17) |
| Binet stage A, B, C† (%) | 26, 94, 46 (16, 56, 28) |
| Time from diagnosis, mo | 13 (0-156) |
| Chemotherapy naïve (%) | 152/167 (91) |
| Serum thymidine kinase > 7 U/L (%) | 97/115 (84) |
| β2M > 3.5 mg/L (%) | 47/115 (41) |
| Lymphocyte doubling time < 12 mo (%) | 55/104 (53) |
| White blood count > 50/nL (%) | 92/162 (57) |
| Characteristic . | Value . |
|---|---|
| Sex, female/male (%) | 28/141 (17/83) |
| Age, y | 51 (27-60) |
| IGHV unfavorable (%) | 87/91 (68) |
| Unmutated* (%) | 84/129 (65) |
| V3-21 mutated (%) | 4/129 (3) |
| FISH karyotype (hierarchical model) | |
| 17p- ± others (%) | 4/160 (2.5) |
| 11q- ± others (except 17p-) (%) | 40/160 (25) |
| +12 ± others (except 17p-, 11q-) (%) | 20/160 (12.5) |
| 13q- only (%) | 48/160 (30) |
| Others (%) | 20/160 (12.5) |
| Normal FISH karyotype (%) | 28/160 (17) |
| Binet stage A, B, C† (%) | 26, 94, 46 (16, 56, 28) |
| Time from diagnosis, mo | 13 (0-156) |
| Chemotherapy naïve (%) | 152/167 (91) |
| Serum thymidine kinase > 7 U/L (%) | 97/115 (84) |
| β2M > 3.5 mg/L (%) | 47/115 (41) |
| Lymphocyte doubling time < 12 mo (%) | 55/104 (53) |
| White blood count > 50/nL (%) | 92/162 (57) |